Immunotherapy CARE Program for Breast Cancer

This trial tests a new program designed to help people with breast cancer manage their immunotherapy treatment more effectively. The researchers aim to determine if this program improves patients' management of their treatment compared to usual care. They will also assess its impact on participants' quality of life through questionnaires. Suitable candidates have breast cancer, are beginning specific immune treatments, and have essential needs such as food or transportation. Participants should reside in the New York metro area and speak English or Spanish. As an unphased trial, this study provides a unique opportunity for patients to contribute to innovative care strategies that could enhance treatment experiences for others.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Past studies on treatments using the body's immune system to fight breast cancer have shown mixed results. Some research suggests these treatments are well-tolerated. For example, one study found that a type of laser treatment was generally accepted by patients and showed promise in treating metastatic breast cancer. However, another study on Keytruda, a specific immune therapy, reported that 41% of patients experienced serious side effects, although it also helped shrink tumors.

Researchers are excited about the Immunotherapy CARE Program for breast cancer because it represents a shift from traditional treatments like chemotherapy and hormone therapy. Unlike these standard options that often target cancer cells directly, this program leverages the body's own immune system to combat cancer, potentially offering more personalized and less toxic treatment. The unique focus on enhancing the immune response could lead to improved outcomes and fewer side effects, making it a promising alternative for patients seeking innovative care.

Research has shown that immunotherapy holds promise for treating breast cancer. In this trial, participants in the I CARE Group will receive the Immunotherapy CARE Program. Studies have found improved outcomes, particularly for patients with specific types of breast cancer. For instance, immunotherapy has led to a 5-year survival rate of over 90% and reduced the risk of recurrence by half. In patients who are PD-L1 positive, one study found that the average survival time was 25 months with immunotherapy. These findings suggest that immunotherapy could be an effective treatment option for some breast cancer patients.²³⁶⁷⁸